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Every newborn carries immense possibility to transform into a complete healthy human being and fulfill the needs the future will demand. Of the newly born babies in our 
country 10–12% are born before 37 completed weeks are called 
premature, compared to 5–7% in the western country [1]. Live-
born infant delivered before 37 weeks from the 1st day of last 
menstrual period are termed as “premature” by the WHO [2]. 
Low birth weight (LBW, birth weight of 2500 g or less) can be 
due to prematurity and intrauterine growth retardation or both. 
Approximately 57% of cases, under the age of 5, mortality 
occurs in a neonatal period of which 36% are attributable to 
prematurity [2,3].
With the evolution of neonatology, better understanding of 
neonatal physiology and advanced care, the intact neurobehavioral 
development survival of these newborn babies; especially, 
those <1000 g has increased to >90% [1]. Of the problems of a 
premature baby, respiratory causes are the most common cause 
of the admission to neonatal intensive care unit (NICU). The 
common respiratory problem is respiratory distress syndrome 
(RDS) or hyaline membrane disease (HMD), whose incidence 
increases as babies are born early [4-7]. It affects 60–80% of 
babies born before 28 weeks, 50% born between 28 and 32 weeks, 
15–30% born between 32 and 36 weeks, and 10% born between 
33 and 34 weeks [4-7]. RDS is an acute illness of preterm infant 
manifesting usually within 6 h characterized clinically by at 2 
of the 3 essential features (NNF India) [8], i.e., (1) tachypnea 
(respiratory rate [RR] >60/min), (2) retractions (Intercostals and 
Subcostal), and (3) expiratory grunt. Downes score (term babies) 
and Silverman-Andersons scores (preterm babies) were used to 
assess the severity of RDS.
Prematurity is the most common etiological factor of RDS, 
and it is primarily due to the inadequate pulmonary surfactants 
with resultant diffuse alveolar atelectasis, edema, and cell injury. 
Prenatal diagnosis to identify the infant at risk, prevention 
of the disease by antenatal steroids, improved neonatal care, 
advances in respiratory support, and surfactant replacement 
therapy (SRT) have dramatically reduced mortality from RDS. 
Systematic reviews of RCT confirmed that SRT reduces initial 
inspired oxygen and ventilation requirements as well as incidence 
of severe RDS, death, pneumothorax, and other morbidity of 
prematurity [9-13]. However, RDS is still an important cause of 
morbidity and mortality in immature infants [14]. The objective 
of this study was to observe the outcome of surfactant therapy for 
RDS among preterm newborns.
MATERIALS AND METHODS
The study was conducted in the NICU of a tertiary care unit, in 
the department of pediatrics, Cuttack, from September 2010 to 
September 2012. Case selection was same in both the groups’, 
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i.e., premature baby (<34 weeks) admitted in NICU with clinical 
signs and symptoms of RDS with X-ray features suggestive of 
RDS, after eliminating other possible differential diagnosis of 
respiratory distress. Cases were defined as respiratory distress 
in a premature baby with any 2 of 3 essential features, i.e., 
tachypnea (RR >60/min), retractions (intercostals and subcostal), 
and expiratory grunt. Newborns >34 weeks of gestation or birth 
weight ≥2000 g, or newborns having respiratory distress due 
to other causes such as surgical, metabolic causes, congenital 
respiratory tract anomaly, birth asphyxia, congenital heart 
disease, meconium aspiration syndrome, and infections including 
congenital pneumonia were excluded from the study. The 
parents who left against medical advice were also omitted from 
observation in both groups.
Parents were counseled about the role of SRT in addition to other 
supportive management. The need for the SRT and mechanical 
ventilation was decided in the presence of the following; Fio2 
>0.35% to maintain Pao2 normal (60–80 mm-Hg) or Sp02 (88–
93%) or having arterial/alveolar oxygen tension ratio (PaO2/PAO2 
or a/A ratio <0.22). Babies, whose parents gave consent for the 
surfactant (and who can afford), were assigned as surfactant group 
while those, who could not afford it, were included in nonsurfactant 
group after matching the general characteristics. Written consent 
of the parents or legal guardians was taken in after explaining 
about the SRT. The adequate amount of surfactant was given to 
the babies while closely monitoring for the vital signs.
Antenatal history focusing history of premature rupture of 
membrane, history of previous pregnancy, doses of antenatal 
steroids, and causes for premature birth were recorded in a 
predesigned pro forma. Significant postnatal events and clinical 
examination findings with gestational age assessment by New 
Ballard scoring were also noted down. All babies in either group 
were started with fluids as per the weight and day of life, broad-
spectrum antibiotic (ampicillin and gentamycin) with other 
supportive therapy on the individual and clinical basis. Routine 
and special investigations were sent on the individual clinical 
basis. In addition, pre-surfactant blood gas analysis and chest 
X-ray were also done.
Surfactant was administered after intubating and confirming 
the position ET tube clinically, and airway secretion was cleared. 
Surfactant was given in 2–3 aliquots with a baby in supine 
position. The patients were manually ventilated after each 
aliquot and simultaneously assessing for adequacy of airway, 
breathing, auscultation, Spo2, chest rise, heart rate, RR, blood 
pressure, pulse, and air entry and were put back on bubble-CPAP 
or mechanical ventilator depending on the clinical condition. No 
suctioning was done unless needed and for minimum 1 h.
Regular monitoring was done for vital signs, requirement of 
oxygen, ventilation settings at 30 min, 1, 6, 12, 24, 36 h, 48 h, 
and 72 h. Blood gas analysis was done after 30 min of SRT and 
as and when required. Chest X-ray 6 h, 24 h after or whenever 
needed to rule out air leak, pneumonia, and ventilator-associated 
pneumonia. Bedside cranial ultrasonography was done between 3 
and 5 days and at discharge. Those babies who improved gradually 
without the complication of disease or intervention were weaned 
from ventilator support and put on oxygen inhalation. Those 
deteriorated appropriate management was provided with close 
monitoring of vital signs.
In both groups complications developed, duration of ventilator 
support, duration of NICU stay, and hospital stay were recorded 
and summarized. Cost of treatment was not assessed in either 
group as the study was performed in a government hospital with 
nominal charges for NICU stay and ventilation.
RESULTS
There were total 103 premature babies; out of the 38 babies meet 
the SRT criteria and given received the surfactant. The rest of 
the 65 babies who were also meeting the criteria for SRT but 
their parents could not afford the surfactant were categorized 
as nonsurfactant group. General characteristics were the same 
in both the groups as shown in Table 1. Since it was a tertiary 
referral center catering babies across the state with poor health 
transportation, there was a delay in administration of surfactant.
Neonatal deaths were more in the nonsurfactant group (28.95% 
vs. 50.76%), and the difference was statistically significant 
(p=0.03). Early neonatal deaths were more in nonsurfactant group 
(51.51%) than in the surfactant group (36.36%) because of less 
death from primary issue, i.e., RDS and its complication. Late 
neonatal deaths were more in the surfactant group (63.63%) than 
in nonsurfactant group (48.48%); however, the difference was not 
statistically significant (Table 2).
Table 1: General characteristics of patients
Characteristics Surfactant (38) No surfactant (65)
Duration of hospitalization (Mean±SD) 11.15±2.85 11.58±2.93
Gestational age in weeks (Mean±SD) 31.13±1.78 31.16±1.82
Birth weight in grams (Mean±SD) 1227.6±233.12 1293±261.74
Male babies (%) 27 (71.05) 40 (61.53)
Antenatal booked pregnancy (%) 30 (78.94) 47 (72.30)
Antenatal steroid (%) (Last dose 24 h before delivery) 16 (42.10) 25 (38.46)
PROM >18 h (%) 11 (28.94) 18 (27.69)
Cesarean delivery 6 (15.78) 16 (24.61)
Average age at which SRT given 14.15±2.83
PROM: Premature rupture of membrane, SD: Standard deviation, SRT: Surfactant replacement therapy
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Overall, total survival was more in surfactant group (71.05%) 
than in nonsurfactant group (49.23%) but comparative survival 
according to gestational age showed the statistically insignificant 
difference (Table 3). Duration of the ventilation and NICU stay 
was significantly more in a nonsurfactant group than in babies 
who received the surfactant (0.02) as shown in Table 4. Overall, 
morbidities among survivors were more in the nonsurfactant 
group, but it was non-significant as shown in Table 5.
DISCUSSION
HMD is the most common indication for the neonatal ventilation 
in our country [9]. The reported survival of babies ventilated 
for HMD varied from 25% to 64% in our country [10,11]. The 
survival till discharge in the babies was significantly less in 
the babies who did not receive surfactant (49.23%), and it was 
comparable to the other reported studies from India [10,11]. 
Table 2: Early neonatal and late neonatal death
Causes of 
deaths










RDS 0 2 (11.76) 1.0 - - --
Air leak 1 (25) 2 (11.76) 0.4 0 1 (6.25) 1.0
IVH 0 2 (11.76) 1.0 - - --
Sepsis 2 (50) 10 (58.82) 1.0 4 (57.14) 10 (62.50) 1.0
Others (NEC, 
PPHN, PDA)
1 (25) 1 (5.88) 0.3 0 2 (12.5) 1.0
Pneumonia - - -- 3 (42.85) 4 (25) 0.6
Total 4/11 (36.36) 17/33 (51.51) 0.4 7/11 (63.63) 16/33 (48.48) 0.4
RDS: Respiratory distress syndrome, IVH: Intraventricular Hemorrhage, NEC: Necrotizing enterocolitis, PPHN: Persistent pulmonary hypertension of the newborn, PDA: Patent 
ductus arteriosus
Table 3: Survival rate according to gestational age
Gestational age Surfactant (38) Nonsurfactant (65) p value
In weeks Number Survival (%) Number Survival (%)
≤27 1 0 (00) 1 0 (00) --
28–29 7 4 (57.14) 13 4 (30.76) 0.3
30–31 13 9 (69.23) 24 8 (33.33) 0.04
32–33 15 12 (80.00) 17 11 (64.70) 0.4
34 2 2 (100) 10 9 (90.00) 1.0
Total 38 27 (71.05) 65 32 (49.23) 0.03
Table 4: Duration of ventilation, ICU, and hospital stay
Observation Surfactant group (27) Nonsurfactant group (32) p value
Duration of ventilation (days) 2.48±0.89 6.09±2.41 0.02
Duration of NICU stay (days) 7.22±2.11 11.96±3.23 0.04
Duration of hospital stay (days) 20.40±6.07 23.65±6.25 0.05
NICU: Neonatal intensive care unit
Table 5: Overall morbidity among survivors
Overall morbidity in survivors Surfactant group n=27 (%) Nonsurfactant 32 (%) p value
Sepsis 14 (51.85) 25 (78.12) 0.05
Pneumonia 11 (40.74) 20 (62.50) 0.12
PDA 3 (11.11) 6 (18.75) 0.2
IVH 1 (3.70) 3 (9.37) 0.6
NEC 3 (11.11) 7 (21.87) 0.3
CLD 1 (3.70) 3 (9.33) 0.6
Others (ROP, PPHN, etc.) 3 (11.11) 7 (21.87) 0.3
PDA: Patent ductus arteriosus, IVH: Intraventricular hemorrhage, NEC: Necrotizing enterocolitis, CLD: Chronic lung disease, ROP: Retinopathy of prematurity, PPHN: 
Persistent pulmonary hypertension of the newborn
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Narang et al. [12] in an Indian study found that the early 
neonatal mortality was significantly lower in surfactant (25%) 
than in the nonsurfactant group (38.7%) and overall survival 
till discharge in surfactant group (62.5%) was significantly 
higher than in nonsurfactant groups (43.7%). Femitha 
et al. [13] in their study found that survival was 71.3% among 
those who received SRT. Bae et al. [15] found neonatal death 
of 40%. Cummings et al. [16] found that the SRT decreased the 
neonatal mortality up to 40%. This difference was due to the 
less complication of RDS, less duration of ventilator support 
and ICU stay, less chances of sepsis, and other complication of 
supportive therapy in the surfactant group than nonsurfactant 
group.
Overall, major cause of mortality was sepsis which was more 
in our study (59%) while it contributed to 49% of neonatal deaths 
in a study by Narang et al. [12]. Bhakoo [17] stated sepsis (67%) 
was the most common complication of the ventilated babies. 
In a study by Narang et al. [12], early neonatal mortality was 
significantly lower in a surfactant (25%) than in the nonsurfactant 
group (38.7%), and septicemia was the most common cause of 
death in both the groups. The better survival in the surfactant 
group may be due to the less complication of RDS, duration of 
ventilation, sepsis, and other intervention.
Sepsis was the most common cause of late neonatal death 
overall contributing to 59% of the deaths, which was more in 
comparison to result from other studies. Bae et al. [15] in a 
study in Korea found sepsis as the major cause of mortality 
(42.6%) in 1996 while Narang et al. [12] reported sepsis 
in 49% of neonatal deaths. The occurrence of infection is 
directly related to the duration of ventilation and hospital 
stay, and the lower incidence of sepsis in the surfactant group 
may be related to the lesser duration of ventilation, ICU stay, 
less need of intervention, and less complication of the disease 
process.
In our study, survival was more in steroid plus surfactant (75%) 
than only steroid (52%). In the study done by Jobe et al. [18] 
concluded that antenatal corticosteroid therapy in threatened 
premature labor combined with the use of postnatal rescue 
surfactant is associated with a decreased incidence of RDS and 
may be beneficial for reducing the severity of RDS and improving 
the eventual outcome of VLBW infants.
CONCLUSION
Our study showed that a single dose of surfactant given in late 
hours in established RDS reduced the duration of mechanical 
ventilation, ICU stay, hospital stay, morbidity, and mortality. 
Sepsis was the major cause of mortality and morbidity and need 
to stress on aseptic delivery protocols and neonatal care.
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